BACKGROUND AND PURPOSE Corticotropin releasing factor is an endogenous neuropeptide released by the hypothalamus that activates the pituitary-adrenocortical system in response to stressful stimuli. It has been demonstrated that corticotropin releasing factor increases the excitability of hippocampal neurons in both in vitro and in vivo studies, which may contribute to neurological injury during...

This case report describes the first established pregnancy after the use of gonadotrophin-releasing hormone (GnRH) antagonist, ganirelix (Org 37462; Organon), to prevent a premature luteinizing hormone surge during ovarian hyperstimulation with recombinant human follicle stimulating hormone (rhFSH). The pregnancy progressed normally and ended with the birth of a healthy boy and a girl after an ...

Objective Coasting can reduce the ovarian hyperstimulation syndrome (OHSS) risk in ovulation induction cycles before intracytoplasmic sperm injection (ICSI). This study aimed to investigate the effect of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist protocols to controlled ovarian hyperstimulation (COH) cycles with coasting on the parameters of ICSI cycles and the outcome. M...

Prolactin-releasing peptide and corticotrophin-releasing hormone R-00402-2003.R1 2 Prolactin-releasing peptide (PrRP) reduces food intake and body weight, and modifies body temperature when administered centrally in rats, suggesting a role in energy homeostasis. However, the mediators of PrRP's actions are unknown. The present study, therefore, firstly examined the possible involvement of the a...

objective: coasting can reduce the ovarian hyperstimulation syndrome (ohss) risk in ovulation induction cycles before intracytoplasmic sperm injection (icsi). this study aimed to investigate the effect of gonadotropin-releasing hormone (gnrh) agonist and gnrh antagonist protocols to controlled ovarian hyperstimulation (coh) cycles with coasting on the parameters of icsi cycles and the outcome. ...

Nude mice bearing xenografts of HT-29 human colon cancer cell line were treated for 4 weeks with a |n-1 rp"| agonist of luteinizing hormone releasing hormone (LH-RH), somatostatin analogue (RC-160), and bombesin/gastrin releasing peptide antagonist (RC-309S). Some inhibitory effect of [D-Trp'| LH-RH microcapsules releasing 25 fig/day on tumor growth was observed that could be due to sex steroid...

OBJECTIVE To compare long GnRH agonist with GnRH antagonist protocol in poor responders. MATERIALS AND METHODS Medical charts of 531 poor responder women undergoing in-vitro fertilization (IVF) cycle at Zeynep Kamil Maternity and Children's Hospital, IVF Center were retrospectively analysed. Those who received at least 300 IU/daily gonadotropin and had ≤3 oocytes retrieved were enrolled in th...